2020 | Abbvie | Rinvoq - 15 mg/tablet | upadacitinib | 02495155 | Rheumatoid arthritis | 16 Jan 2020 | Within Guidelines |
2020 | Abbvie | Humira - 20 mg/syringe | adalimumab | 02474263 | Rheumatoid arthritis | 18 Aug 2020 | Under Review |
2020 | Advanced Accelerator Applications | Netspot - 40 mcg/kit | oxodotreotide | 02490005 | Cancer | 11 Dec 2019 | Under Review |
2020 | ALK-Abello A S | Itulatek - 12 unit/tablet | Standardized Allergen Extract, White Birch (Betula Verrucosa) | 02498073 | Allergy Immunotherapy | 30 Sep 2020 | Under Review |
2020 | Alnylam Pharmaceuticals, Inc | Givlaari - 189 mg/mL | givosiran | 02506343 | Acute hepatic porphyria | 01 Dec 2020 | Under Review |
2020 | Amgen Canada Inc. | Kanjinti - 420 mg/vial | trastuzumab | 02496690 | Cancer | 16 Apr 2020 | Within Guidelines |
2020 | Aralez Pharmaceuticals Inc. | Suvexx 85/500 - 585 mg/tablet | sumatriptan/naproxen sodium | 02496305 | Migraine | 24 Aug 2020 | Under Review |
2020 | Astellas Pharma Canada Inc. | Xospata - 40 mg/tablet | gilteritinib | 02495058 | Cancer | 04 Feb 2020 | Subject to Investigation |
2020 | Astrazeneca Canada Inc. | Lokelma - 10 g/sachet | sodium zirconium cyclosilicate | 02490722 | Hyperkalemia | 17 Oct 2019 | Subject to Investigation |
2020 | Astrazeneca Canada Inc. | Lokelma - 5 g/sachet | sodium zirconium cyclosilicate | 02490714 | Hyperkalemia | 17 Oct 2019 | Subject to Investigation |
2020 | Bausch Health, Canada Inc. | Duobrii 0.1/0.45 - 0.55 mg/mL | halobetasol Propionate/Tazarotene | 02499967 | Moderate-to-severe plaque psoriasis | 04 Aug 2020 | Under Review |
2020 | Bayer Inc. | Nubeqa - 300 mg/tablet | darolutamide | 02496348 | Cancer | 24 Mar 2020 | Within Guidelines |
2020 | Bayer Inc. | Nubeqa - 300 mg/tablet | darolutamide | 02496348 | Cancer | 24 Mar 2020 | Within Guidelines |
2020 | Bayer Inc. | Jivi | antihemophilic factor (recombinant, b-domain deleted, pegylated) | 02481766 | Hemophilia A | 08 Apr 2020 | Within Guidelines |
2020 | Bayer Inc. | Jivi | antihemophilic factor (recombinant, b-domain deleted, pegylated) | 02481774 | Hemophilia A | 11 Mar 2020 | Within Guidelines |
2020 | Bayer Inc. | Jivi | antihemophilic factor (recombinant, b-domain deleted, pegylated) | 02481782 | Hemophilia A | 27 Jan 2020 | Within Guidelines |
2020 | Bayer Inc. | Jivi | antihemophilic factor (recombinant, b-domain deleted, pegylated) | 02481790 | Hemophilia A | 27 Jan 2020 | Within Guidelines |
2020 | Bayer Inc. | Eylea - 40 mg/mL | aflibercept | 02505355 | Neovascular (wet) age-related macular degeneration | 17 Nov 2020 | Within Guidelines |
2020 | Bayer Inc. | Vitrakvi - 100 mg/capsule | larotrectinib | 02490323 | Cancer | 17 Nov 2020 | Under Review |
2020 | Biomarin Pharmaceutical Canada Inc. | Kuvan - 100 mg/sachet | sapropterin dihydrochloride | 02482207 | Phenylketonuria | 05 Dec 2019 | Within Guidelines |
2020 | Biomarin Pharmaceutical Canada Inc. | Kuvan - 500 mg/sachet | sapropterin dihydrochloride | 02482215 | Phenylketonuria | 05 Dec 2019 | Within Guidelines |
2020 | Celgene Inc | Zeposia - 0.92 mg/capsule | ozanimod | 02505991 | Multiple sclerosis | 12 Nov 2020 | Under Review |
2020 | Celgene Inc | Zeposia 0.23/0.46 - 1 N.A./kit | ozanimod | 02506009 | Multiple sclerosis | 12 Nov 2020 | Under Review |
2020 | Celgene Inc | Reblozyl - 25 mg/vial | luspatercept | 02505541 | beta-thalassemia | 23 Nov 2020 | Under Review |
2020 | Celgene Inc | Reblozyl - 75 mg/vial | luspatercept | 02505568 | beta-thalassemia | 23 Nov 2020 | Under Review |
2020 | Chiesi USA, Inc. | Cleviprex - 0.5 mg/mL | clevidipine | 02366223 | Hypertension | 10 Dec 2019 | Subject to Investigation |
2020 | Eisai Limited | Dayvigo - 5 mg/tablet | lemborexant | 02507366 | Insomnia | 06 Nov 2020 | Under Review |
2020 | Eisai Limited | Dayvigo - 10 mg/tablet | lemborexant | 02507374 | Insomnia | 06 Nov 2020 | Under Review |
2020 | Eli Lilly Canada Inc. | Lartruvo - 190 mg/vial | olaratumab | 02480271 | Cancer | 09 Jun 2020 | Under Review |
2020 | Gilead Sciences Canada Inc | Velkury - 100 mg/vial | remdesivir | 02502143 | COVID-19 | 16 Oct 2020 | Under Review |
2020 | Glaxosmithkline Inc. | Zejula - 100 mg/capsule | niraparib tosylate | 02489783 | Cancer | 09 Jan 2020 | Subject to Investigation |
2020 | Hoffmann-La Roche Limited | Rozlytrek - 200 mg/capsule | entrectinib capsules | 02495015 | Cancer | 03 Jun 2020 | Under Review |
2020 | Hoffmann-La Roche Limited | Enspryng - 120 mg/mL | satralizumab | 02499681 | neuromyelitis optica spectrum disorders | 18 Sep 2020 | Under Review |
2020 | Hoffmann-La Roche Limited | Polivy - 140 mg/vial | polatuzumab vedotin | 02499614 | Cancer | 25 Nov 2020 | Under Review |
2020 | Janssen Inc. | Darzalex SC - 120 mg/mL | daratumumab injection | 02502712 | Multiple myeloma | 21 Aug 2020 | Under Review |
2020 | Janssen Inc. | Balversa - 3 mg/tablet | erdafitinib | 02493217 | Cancer | 16 Dec 2019 | Within Guidelines |
2020 | Janssen Inc. | Balversa - 4 mg/tablet | erdafitinib | 02493225 | Cancer | 11 Dec 2019 | Within Guidelines |
2020 | Janssen Inc. | Balversa - 5 mg/tablet | erdafitinib | 02493233 | Cancer | 16 Dec 2019 | Within Guidelines |
2020 | Novartis Pharmaceuticals Canada Inc. | Atectura Breezhaler 150/160 - 310 mcg/capsule | indacaterol acetate / mometasone furoate | 02498707 | Asthma | 19 Aug 2020 | Under Review |
2020 | Novartis Pharmaceuticals Canada Inc. | Atectura Breezhaler 150/320 - 470 mcg/capsule | indacaterol acetate / mometasone furoate | 02498693 | Asthma | 19 Aug 2020 | Under Review |
2020 | Novartis Pharmaceuticals Canada Inc. | Atectura Breezhaler 150/80 - 230 mcg/capsule | indacaterol acetate / mometasone furoate | 02498685 | Asthma | 19 Aug 2020 | Under Review |
2020 | Novartis Pharmaceuticals Canada Inc. | Beovu - 120 mg/mL | brolucizumab | 02496976 | Neovascular (wet) age-related macular degeneration | 15 May 2020 | Does Not Trigger Investigation |
2020 | Novartis Pharmaceuticals Canada Inc. | Mayzent - 0.25 mg/tablet | siponimod | 02496429 | Multiple sclerosis | 24 Apr 2020 | Within Guidelines |
2020 | Novartis Pharmaceuticals Canada Inc. | Mayzent - 2 mg/tablet | siponimod | 02496437 | Multiple sclerosis | 24 Apr 2020 | Within Guidelines |
2020 | Novartis Pharmaceuticals Canada Inc. | Enerzair Breezhaler 150/50/160 - 360 mcg/capsule | indacaterol acetate / glycopyrronium bromide / mometasone furoate | 02501244 | Asthma | 05 Nov 2020 | Under Review |
2020 | Novartis Pharmaceuticals Canada Inc. | Piqray - 150 mg/tablet | alpelisib | 02497069 | Cancer | 29 Jun 2020 | Under Review |
2020 | Novartis Pharmaceuticals Canada Inc. | Piqray - 250 mg/tablet | alpelisib | 02497077 | Cancer | 29 Jun 2020 | Under Review |
2020 | Novartis Pharmaceuticals Canada Inc. | Piqray 50/200 - 250 mg/tablet | alpelisib | 02497085 | Cancer | 29 Jun 2020 | Under Review |
2020 | Novartis Pharmaceuticals Canada Inc. | Zolgensma | onasemnogene abeparvovec | 02509695 | Spinal Muscular Atrophy | 22 Sep 2020 | Under Review |
2020 | Pfizer Canada Inc. | Ibrance - 75 mg/tablet | palbociclib | 02493535 | Cancer | 21 Sep 2020 | Under Review |
2020 | Pfizer Canada Inc. | Ibrance - 100 mg/tablet | palbociclib | 02493543 | Cancer | 21 Sep 2020 | Under Review |
2020 | Pfizer Canada Inc. | Ibrance - 125 mg/tablet | palbociclib | 02493551 | Cancer | 21 Sep 2020 | Under Review |
2020 | Pfizer Canada Inc. | GENOTROPIN MiniQuick - 0.2 MG/syringe | somatropin | 02401746 | Growth hormone deficiency | 17 Sep 2020 | Under Review |
2020 | Pfizer Canada Inc. | GENOTROPIN MiniQuick - 0.4 MG/syringe | somatropin | 02401754 | Growth hormone deficiency | 17 Sep 2020 | Under Review |
2020 | Pfizer Canada Inc. | Vyndaqel - 20 mg/capsule | tafamidis meglumine | 02495732 | Heart | 13 Apr 2020 | Within Guidelines |
2020 | Sanofi-Aventis Canada Inc. | Toujeo DoubleStar - 300 unit/mL | insulin glargine | 02493373 | Type 2 diabetes mellitus | 04 Feb 2020 | Within Guidelines |
2020 | Sanofi-Aventis Canada Inc. | Sarclisa - 100 mg/vial | isatuximab | 02498235 | Multiple myeloma | 03 Jul 2020 | Under Review |
2020 | Sanofi-Aventis Canada Inc. | Sarclisa - 500 mg/vial | isatuximab | 02498243 | Multiple myeloma | 03 Jul 2020 | Under Review |
2020 | Seattle Genetics Inc. | Tukysa - 150 mg/tablet - 0.55 mg/mL | tucatinib | 02499835 | Cancer | 27 Aug 2020 | Under Review |
2020 | Seattle Genetics Inc. | Tukysa - 50 mg/tablet | tucatinib | 02499835 | Cancer | 08 Oct 2020 | Under Review |
2020 | Sunovion Pharmaceuticals Canada Inc. | Kynmobi - 10 mg/film | apomorphine hydrochloride | 02500264 | Parkinson's disease | 17 Nov 2020 | Within Guidelines |
2020 | Sunovion Pharmaceuticals Canada Inc. | Kynmobi - 15 mg/film | apomorphine hydrochloride | 02500272 | Parkinson's disease | 17 Nov 2020 | Within Guidelines |
2020 | Sunovion Pharmaceuticals Canada Inc. | Kynmobi - 20 mg/film | apomorphine hydrochloride | 02500280 | Parkinson's disease | 17 Nov 2020 | Within Guidelines |
2020 | Sunovion Pharmaceuticals Canada Inc. | Kynmobi - 25 mg/film | apomorphine hydrochloride | 02500299 | Parkinson's disease | 17 Nov 2020 | Within Guidelines |
2020 | Sunovion Pharmaceuticals Canada Inc. | Kynmobi - 30 mg/film | apomorphine hydrochloride | 02500302 | Parkinson's disease | 17 Nov 2020 | Within Guidelines |
2020 | Tahio Pharma Canada | Inqovi 35/100 - 135 mg/tablet | decitabine /cedazuridine | 02501600 | myelodysplastic syndromes | 11 Nov 2020 | Under Review |
2020 | Takeda Canada Inc. | Adynovate - 3000 IU/vial | antihemophilic Factor (Recombinant), PEGylated | 02498626 | Hemophilia A | 15 Sep 2020 | Under Review |
2020 | Takeda Canada Inc. | Entyvio - 108 mg/pen | vedolizumab | 02497867 | Ulcerative colitis | 08 Jul 2020 | Under Review |
2020 | Takeda Canada Inc. | Entyvio - 108 mg/syringe | vedolizumab | 02497875 | Ulcerative colitis | 20 Nov 2020 | Under Review |
2020 | Teva Canada Innovation G.P.-S.E.N.C | Aermony Respiclick - 55 mcg/actuation | fluticasone propionate | 02467895 | Asthma | 30 Sep 2020 | Under Review |
2020 | Teva Canada Innovation G.P.-S.E.N.C | Aermony Respiclick - 113 mcg/actuation | fluticasone propionate | 02467909 | Asthma | 30 Sep 2020 | Under Review |
2020 | Teva Canada Innovation G.P.-S.E.N.C | Aermony Respiclick - -232 mcg/actuation | fluticasone propionate | 02467917 | Asthma | 30 Sep 2020 | Under Review |
2020 | Teva Canada Innovation G.P.-S.E.N.C. | Ajovy - 150 mg/mL | fremanezumab | 02497859 | Migraine | 04 Aug 2020 | Under Review |
2020 | UCB Canada Inc. | Brivlera - 10 mg/mL | brivaracetam | 02452987 | Epilepsy | 06 Apr 2020 | Within Guidelines |
2020 | Vertex Pharmaceuticals Canada Inc. | elexacaftor/tezacaftor/ivacaftor and ivacaftor - 1 N.A./pack | elexacaftor/tezacaftor/ivacaftor and ivacaftor | | Cystic fibrosis | 22 Jan 2020 | Under Review |
2020 | Viiv Healthcare Ulc | Cabenuva 200/300 - 500 mg/mL | cabotegravir/rilpivirine | 02497220 | HIV | 21 Sep 2020 | Under Review |
2020 | Viiv Healthcare Ulc | Cabenuva 200/300 - 500 mg/mL | cabotegravir/rilpivirine | 02497247 | HIV | 21 Sep 2020 | Under Review |
2020 | Viiv Healthcare Ulc | Vocabria - 30 mg/tablet | cabotegravir | 02497204 | HIV | 21 Sep 2020 | Under Review |